Cargando…

Monthly administrations of milbemycin oxime plus afoxolaner chewable tablets to prevent Angiostrongylus vasorum infection in dogs

BACKGROUND: Infection of dogs with the cardiopulmonary nematode Angiostrongylus vasorum may result in severe clinical disease therefore adequate prevention is necessary. A randomized, negative control, blinded study was conducted to evaluate the efficacy in the prevention of canine A. vasorum infect...

Descripción completa

Detalles Bibliográficos
Autores principales: Lebon, Wilfried, Tielemans, Eric, Rehbein, Steffen, Dumont, Pascal, Yoon, Stephen, Beugnet, Fredéric, Jeannin, Philippe, Larsen, Diane, Halos, Lénaïg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010729/
https://www.ncbi.nlm.nih.gov/pubmed/27589951
http://dx.doi.org/10.1186/s13071-016-1773-1
_version_ 1782451726941421568
author Lebon, Wilfried
Tielemans, Eric
Rehbein, Steffen
Dumont, Pascal
Yoon, Stephen
Beugnet, Fredéric
Jeannin, Philippe
Larsen, Diane
Halos, Lénaïg
author_facet Lebon, Wilfried
Tielemans, Eric
Rehbein, Steffen
Dumont, Pascal
Yoon, Stephen
Beugnet, Fredéric
Jeannin, Philippe
Larsen, Diane
Halos, Lénaïg
author_sort Lebon, Wilfried
collection PubMed
description BACKGROUND: Infection of dogs with the cardiopulmonary nematode Angiostrongylus vasorum may result in severe clinical disease therefore adequate prevention is necessary. A randomized, negative control, blinded study was conducted to evaluate the efficacy in the prevention of canine A. vasorum infection after monthly administrations of NexGard Spectra®, a novel chewable tablet formulation combining the insecticide and acaricide afoxolaner and the anthelmintic milbemycin oxime, in a multiple challenge (trickle infection) model. METHODS: Twenty beagle dogs were challenged orally with doses of approximately 32–43 third-stage larvae of A. vasorum once every other week on seven occasions (Study Days -7, 7, 21, 35, 49, 63 and 77). Ten dogs were administered NexGard Spectra® as close as possible to the minimum recommended dose of afoxolaner and milbemycin oxime, i.e. 2.5 mg/kg body weight and 0.5 mg/kg body weight, respectively, four times at monthly intervals (Study Days 0, 28, 56 and 84) while the remaining ten dogs served as untreated controls. For parasite recovery and count, dogs were euthanized humanely and necropsied six to eight days following the last treatment (Study Days 90–92). Beginning six weeks after first inoculation, faeces were collected on a bi-weekly basis and examined for first-stage larvae of A. vasorum. RESULTS: Untreated dogs harboured 39–95 adult A. vasorum (geometric mean, 66.4), while zero to 24 adult A. vasorum were recovered from the treated dogs (geometric mean, 3.4; P < 0.0001). Thus, efficacy of NexGard Spectra® administered at monthly intervals against incoming A. vasorum was 94.9 %. Compared to the untreated controls, larval excretion of the treated dogs was reduced by 99.9 % (P < 0.0001). CONCLUSION: Results of this study demonstrate that NexGard Spectra®, when administered at monthly intervals, can effectively prevent canine A. vasorum infection.
format Online
Article
Text
id pubmed-5010729
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50107292016-09-04 Monthly administrations of milbemycin oxime plus afoxolaner chewable tablets to prevent Angiostrongylus vasorum infection in dogs Lebon, Wilfried Tielemans, Eric Rehbein, Steffen Dumont, Pascal Yoon, Stephen Beugnet, Fredéric Jeannin, Philippe Larsen, Diane Halos, Lénaïg Parasit Vectors Research BACKGROUND: Infection of dogs with the cardiopulmonary nematode Angiostrongylus vasorum may result in severe clinical disease therefore adequate prevention is necessary. A randomized, negative control, blinded study was conducted to evaluate the efficacy in the prevention of canine A. vasorum infection after monthly administrations of NexGard Spectra®, a novel chewable tablet formulation combining the insecticide and acaricide afoxolaner and the anthelmintic milbemycin oxime, in a multiple challenge (trickle infection) model. METHODS: Twenty beagle dogs were challenged orally with doses of approximately 32–43 third-stage larvae of A. vasorum once every other week on seven occasions (Study Days -7, 7, 21, 35, 49, 63 and 77). Ten dogs were administered NexGard Spectra® as close as possible to the minimum recommended dose of afoxolaner and milbemycin oxime, i.e. 2.5 mg/kg body weight and 0.5 mg/kg body weight, respectively, four times at monthly intervals (Study Days 0, 28, 56 and 84) while the remaining ten dogs served as untreated controls. For parasite recovery and count, dogs were euthanized humanely and necropsied six to eight days following the last treatment (Study Days 90–92). Beginning six weeks after first inoculation, faeces were collected on a bi-weekly basis and examined for first-stage larvae of A. vasorum. RESULTS: Untreated dogs harboured 39–95 adult A. vasorum (geometric mean, 66.4), while zero to 24 adult A. vasorum were recovered from the treated dogs (geometric mean, 3.4; P < 0.0001). Thus, efficacy of NexGard Spectra® administered at monthly intervals against incoming A. vasorum was 94.9 %. Compared to the untreated controls, larval excretion of the treated dogs was reduced by 99.9 % (P < 0.0001). CONCLUSION: Results of this study demonstrate that NexGard Spectra®, when administered at monthly intervals, can effectively prevent canine A. vasorum infection. BioMed Central 2016-09-02 /pmc/articles/PMC5010729/ /pubmed/27589951 http://dx.doi.org/10.1186/s13071-016-1773-1 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lebon, Wilfried
Tielemans, Eric
Rehbein, Steffen
Dumont, Pascal
Yoon, Stephen
Beugnet, Fredéric
Jeannin, Philippe
Larsen, Diane
Halos, Lénaïg
Monthly administrations of milbemycin oxime plus afoxolaner chewable tablets to prevent Angiostrongylus vasorum infection in dogs
title Monthly administrations of milbemycin oxime plus afoxolaner chewable tablets to prevent Angiostrongylus vasorum infection in dogs
title_full Monthly administrations of milbemycin oxime plus afoxolaner chewable tablets to prevent Angiostrongylus vasorum infection in dogs
title_fullStr Monthly administrations of milbemycin oxime plus afoxolaner chewable tablets to prevent Angiostrongylus vasorum infection in dogs
title_full_unstemmed Monthly administrations of milbemycin oxime plus afoxolaner chewable tablets to prevent Angiostrongylus vasorum infection in dogs
title_short Monthly administrations of milbemycin oxime plus afoxolaner chewable tablets to prevent Angiostrongylus vasorum infection in dogs
title_sort monthly administrations of milbemycin oxime plus afoxolaner chewable tablets to prevent angiostrongylus vasorum infection in dogs
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010729/
https://www.ncbi.nlm.nih.gov/pubmed/27589951
http://dx.doi.org/10.1186/s13071-016-1773-1
work_keys_str_mv AT lebonwilfried monthlyadministrationsofmilbemycinoximeplusafoxolanerchewabletabletstopreventangiostrongylusvasoruminfectionindogs
AT tielemanseric monthlyadministrationsofmilbemycinoximeplusafoxolanerchewabletabletstopreventangiostrongylusvasoruminfectionindogs
AT rehbeinsteffen monthlyadministrationsofmilbemycinoximeplusafoxolanerchewabletabletstopreventangiostrongylusvasoruminfectionindogs
AT dumontpascal monthlyadministrationsofmilbemycinoximeplusafoxolanerchewabletabletstopreventangiostrongylusvasoruminfectionindogs
AT yoonstephen monthlyadministrationsofmilbemycinoximeplusafoxolanerchewabletabletstopreventangiostrongylusvasoruminfectionindogs
AT beugnetfrederic monthlyadministrationsofmilbemycinoximeplusafoxolanerchewabletabletstopreventangiostrongylusvasoruminfectionindogs
AT jeanninphilippe monthlyadministrationsofmilbemycinoximeplusafoxolanerchewabletabletstopreventangiostrongylusvasoruminfectionindogs
AT larsendiane monthlyadministrationsofmilbemycinoximeplusafoxolanerchewabletabletstopreventangiostrongylusvasoruminfectionindogs
AT haloslenaig monthlyadministrationsofmilbemycinoximeplusafoxolanerchewabletabletstopreventangiostrongylusvasoruminfectionindogs